Danaher is finally turning the corner. CNBC's Jim Cramer sees it. Wall Street does, too.
Get this delivered to your inbox, and more info about our products and services.
Life sciences stocks are seeing a resurgence — and that's good news for Danaher.
Danaher's rebound is generating optimism, but there's still work ahead for the company to hit is 2026 growth targets.
CNBC's Jim Cramer made the list and shared it with Club members during Friday's December Monthly Meeting.
The supplier of tools to drugmakers and hospitals is set up for a stronger 2026.
While the quarter was solid and 2026 is shaping up to be better than 2025, the progress has been slower than we would like.
Go behind the scenes with Jim Cramer and Jeff Marks of the CNBC Investing Club as they talk candidly about the market's biggest…
